Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.
about
Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal managementPotential role of tedizolid phosphate in the treatment of acute bacterial skin infectionsCurrent updates on oxazolidinone and its significanceResistance to linezolid caused by modifications at its binding site on the ribosomeTargeting Antibiotic ResistancePlatelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.Tedizolid Phosphate: a Next-Generation Oxazolidinone.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Antibiotics and bacterial resistance in the 21st century.Investigational antimicrobial agents of 2013.The evolving role of chemical synthesis in antibacterial drug discovery.Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene.Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalisAntimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.Emergence and spread of cfr-mediated multiresistance in staphylococci: an interdisciplinary challenge.The oxazolidinones: past, present, and future.Antibiotics in development targeting protein synthesis.The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance.Current strategies for the treatment of complicated intraabdominal infections.Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.Tedizolid for treatment of acute bacterial skin and skin structure infections.Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report.Oxazolidinone antimicrobials: a patent review (2012-2015).Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.Comparative Pharmacokinetic Study for Linezolid and Two Novel Antibacterial Oxazolidinone Derivatives in Rabbits: Can Differences in the Pharmacokinetic Properties Explain the Discrepancies between Their In Vivo and In Vitro Antibacterial ActivitiesIdentification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center.Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05.Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France.In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria.Antimicrobial and anti-biofilm activity of hexadentated macrocyclic complex of copper (II) derived from thiosemicarbazide against Staphylococcus aureus.Copper Catalyzed Assembly ofN-Aryloxazolidinones: Synthesis of Linezolid, Tedizolid, and Rivaroxaban
P2860
Q26798630-E0FE642C-F7CC-4B40-9306-7D8FCED77C48Q26853612-511ECA34-7DFE-4B37-9FC2-D21CE6941214Q26995628-EB565CA3-9861-4C75-A769-BCFD63C277A2Q27006772-88FC07E0-53AB-4745-8719-F058DD5C974BQ28078130-E59DF483-1BAC-4A7B-92E9-38F7ED0FF86AQ33417790-D0F727D1-A08C-4FE4-9A61-A9B4C402ABC6Q33420646-C8AF2731-06A8-4B38-B6AA-664C2371C4FCQ33438834-38B24AD3-81A2-44FF-85BF-A45C16CD8140Q34156349-1ABD268E-3B5C-4663-8E35-DA0E02BEAD44Q34375204-02001FF5-EC45-4DA0-ABCB-F17D6A65B366Q34427652-E715F1EC-0EEF-4648-A27A-815A77FA74EAQ34596580-05FEAFB0-75D2-46B3-BA77-6D0B02860093Q36086317-CB0A6922-D6CE-4882-BA83-39C663E97C3DQ36156072-450E588D-5E7D-4823-9056-686DD5D13204Q36171683-30DD2E74-6A0F-4D35-8B08-5A4C36F9A37BQ37921295-CD2FC196-9FAC-47BB-B39A-77B0DF0EFD49Q37970719-BECFA170-B5B7-42DC-A10A-15B64B9A1F3AQ37970724-B3249A75-7D3D-461C-A690-856E8C2FC7C2Q37972308-F639BC40-4DA3-4D33-B212-A6D43A7FBE93Q38123247-CF3A728E-239D-4CD3-B041-D9EF4AA5F1D2Q38255366-D349E134-9EE8-4938-8BFB-7C0CD9D8D666Q38352171-7E1BB787-BAF3-46C1-84B9-F22842EC54E3Q38536296-FD53BBD2-FBF3-40DB-9CE7-5EA411BA6144Q38554583-CA728E19-A25E-43EA-8665-5E216F973A13Q38641810-ED32FFD1-E70F-44E2-9E52-898D5C806FC5Q38783047-46A17893-6A78-4732-A02B-5ACC04401D99Q38958278-E4F1FA65-C8AF-47FB-BEFA-80CFDCEA7DCAQ41732849-BCB93EA9-FD59-4AC9-B5BC-F2F9F70D1B17Q42363575-F30DF8FE-CE50-43DD-A276-E0901867A709Q42366838-2295E511-870D-486D-A273-E9238759CF66Q43045759-BC5A6376-D03C-466C-B3C7-7B4726F08D13Q43053544-76736981-B9C7-4BF5-950F-74A8FF9B74AFQ47577709-CCBAB5A3-D7C0-42AF-91E4-1997E117FAACQ50855186-659C783C-F0DB-4A95-ACA4-121B6E8ED669Q55315208-BB9B6609-64FE-47EC-B8CE-4DF46D663A2BQ57310724-8F067AB8-D2E6-4B0C-911D-30A6ED0D30F1
P2860
Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Structure-activity relationshi ...... e gene or ribosomal mutations.
@en
type
label
Structure-activity relationshi ...... e gene or ribosomal mutations.
@en
prefLabel
Structure-activity relationshi ...... e gene or ribosomal mutations.
@en
P2093
P2860
P356
P1476
Structure-activity relationshi ...... se gene or ribosomal mutations
@en
P2093
Gracia Morales
Jeffrey B Locke
Jeffrey L Stein
Juan José Picazo
Mark Hilgers
Shahad Rahawi
Weonbin Im
P2860
P304
P356
10.1128/AAC.00663-10
P407
P50
P577
2010-09-13T00:00:00Z